Athena F Zuppa1,2, Nicole R Zane1, Ganesh Moorthy1,2, Heidi J Dalton3, Alan Abraham, Ron W Reeder4, Joseph A Carcillo5, Andrew R Yates6, Kathleen L Meert7, Robert A Berg2, Anil Sapru8, Peter Mourani9, Daniel A Notterman10, J Michael Dean4, Marc R Gastonguay11. 1. Center for Clinical Pharmacology, The Children's Hospital of Philadelphia, Philadelphia, PA. 2. Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA. 3. Adult and Pediatric ECLS, INOVA Fairfax Hospital, Falls Church, VA. 4. Department of Pediatrics, University of Utah, Salt Lake City, UT. 5. Department of Critical Care Medicine, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA. 6. Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, OH. 7. Department of Pediatrics, Children's Hospital of Michigan, Wayne State University, Detroit, MI. 8. Division of Critical Care, UCLA Mattel Children's Hospital, Los Angeles, CA. 9. Section of Critical Care, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO. 10. Department of Molecular Biology, Princeton University, Princeton, NJ. 11. Metrum Research Group, Tariffville, CT.
Abstract
OBJECTIVES: Limited data exist on the effects of extracorporeal membrane oxygenation on pharmacokinetics of cefepime in critically ill pediatric patients. The objective was to describe cefepime disposition in children treated with extracorporeal membrane oxygenation using population pharmacokinetic modeling. DESIGN: Multicenter, prospective observational study. SETTING: The pediatric and cardiac ICUs of six sites of the Collaborative Pediatric Critical Care Research Network. PATIENTS: Seventeen critically ill children (30 d to < 2 yr old) on extracorporeal membrane oxygenation who received cefepime as standard of care between January 4, 2014, and August 24, 2015, were enrolled. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A pharmacokinetic model was developed to evaluate cefepime disposition differences due to extracorporeal membrane oxygenation. A two-compartment model with linear elimination, weight effects on clearance, intercompartmental clearance (Q), central volume of distribution (V1), and peripheral volume of distribution (V2) adequately described the data. The typical value of clearance in this study was 7.1 mL/min (1.9 mL/min/kg) for a patient weighing 5.8 kg. This value decreased by approximately 40% with the addition of renal replacement therapy. The typical value for V1 was 1,170 mL. In the setting of blood transfusions, V1 increased by over two-fold but was reduced with increasing age of the extracorporeal membrane oxygenation circuit oxygenator. CONCLUSIONS: Cefepime clearance was reduced in pediatric patients treated with extracorporeal membrane oxygenation compared with previously reported values in children not receiving extracorporeal membrane oxygenation. The model demonstrated that the age of the extracorporeal membrane oxygenation circuit oxygenator is inversely correlated to V1. For free cefepime, only 14 of the 19 doses (74%) demonstrated a fT_minimum inhibitory concentration of 16 mg/L, an appropriate target for the treatment of pseudomonal infections, for greater than 70% of the dosing interval. Pediatric patients on extracorporeal membrane oxygenation might benefit from the addition of therapeutic drug monitoring of cefepime to assure appropriate dosing.
OBJECTIVES: Limited data exist on the effects of extracorporeal membrane oxygenation on pharmacokinetics of cefepime in critically ill pediatric patients. The objective was to describe cefepime disposition in children treated with extracorporeal membrane oxygenation using population pharmacokinetic modeling. DESIGN: Multicenter, prospective observational study. SETTING: The pediatric and cardiac ICUs of six sites of the Collaborative Pediatric Critical Care Research Network. PATIENTS: Seventeen critically ill children (30 d to < 2 yr old) on extracorporeal membrane oxygenation who received cefepime as standard of care between January 4, 2014, and August 24, 2015, were enrolled. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A pharmacokinetic model was developed to evaluate cefepime disposition differences due to extracorporeal membrane oxygenation. A two-compartment model with linear elimination, weight effects on clearance, intercompartmental clearance (Q), central volume of distribution (V1), and peripheral volume of distribution (V2) adequately described the data. The typical value of clearance in this study was 7.1 mL/min (1.9 mL/min/kg) for a patient weighing 5.8 kg. This value decreased by approximately 40% with the addition of renal replacement therapy. The typical value for V1 was 1,170 mL. In the setting of blood transfusions, V1 increased by over two-fold but was reduced with increasing age of the extracorporeal membrane oxygenation circuit oxygenator. CONCLUSIONS: Cefepime clearance was reduced in pediatric patients treated with extracorporeal membrane oxygenation compared with previously reported values in children not receiving extracorporeal membrane oxygenation. The model demonstrated that the age of the extracorporeal membrane oxygenation circuit oxygenator is inversely correlated to V1. For free cefepime, only 14 of the 19 doses (74%) demonstrated a fT_minimum inhibitory concentration of 16 mg/L, an appropriate target for the treatment of pseudomonal infections, for greater than 70% of the dosing interval. Pediatric patients on extracorporeal membrane oxygenation might benefit from the addition of therapeutic drug monitoring of cefepime to assure appropriate dosing.
Authors: Ann Versporten; Julia Bielicki; Nico Drapier; Mike Sharland; Herman Goossens Journal: J Antimicrob Chemother Date: 2016-01-08 Impact factor: 5.790
Authors: Kiran Shekar; Jason A Roberts; Charles I Mcdonald; Stephanie Fisquet; Adrian G Barnett; Daniel V Mullany; Sussan Ghassabian; Steven C Wallis; Yoke L Fung; Maree T Smith; John F Fraser Journal: Crit Care Date: 2012-10-15 Impact factor: 9.097
Authors: Jin Wi; Min Jung Chang; Soyoung Kang; June Young Jang; Jongsung Hahn; Dasohm Kim; Jun Yeong Lee; Kyoung Lok Min; Seungwon Yang Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz Journal: Clin Pharmacokinet Date: 2022-06-29 Impact factor: 5.577
Authors: Ganesh S Moorthy; Christina Vedar; Nicole R Zane; Kevin J Downes; Janice L Prodell; Mary Ann DiLiberto; Athena F Zuppa Journal: J Pharm Biomed Anal Date: 2019-11-20 Impact factor: 3.935